NAUT Stock Price, Nautilus Biotechnology, . Quote, Chart

Market Summary

USD2.97+0.05

Market Closed

1.71%

NAUT Stock Price

View Fullscreen

NAUT RSI Chart

NAUT Valuation

Market Cap

372.0M

Price/Earnings (Trailing)

-5.52

Price/Free Cashflow

-6.43

NAUT Price/Earnings (Trailing)

NAUT Profitability

Return on Equity

-27.03%

Return on Assets

-23.36%

Free Cashflow Yield

-15.55%

NAUT Fundamentals

NAUT Earnings

Earnings (TTM)

-67.4M

Earnings Growth (Yr)

-25.16%

Earnings Growth (Qtr)

-10.02%

Breaking Down NAUT Revenue

Last 7 days

8.4%

Last 30 days

22.2%

Last 90 days

5.0%

Trailing 12 Months

26.4%

How does NAUT drawdown profile look like?

NAUT Financial Health

Current Ratio

20.09

NAUT Investor Care

Shares Dilution (1Y)

0.32%

Diluted EPS (TTM)

-0.55

Tracking the Latest Insider Buys and Sells of Nautilus Biotechnology, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 11, 2024	patel sujal m	bought	34,215	2.8409	12,044	ceo, president, and secretary
Mar 08, 2024	patel sujal m	bought	7,262	2.9885	2,430	ceo, president, and secretary
Mar 07, 2024	patel sujal m	bought	54,424	2.8866	18,854	ceo, president, and secretary
Mar 06, 2024	patel sujal m	bought	25,033	2.7014	9,267	ceo, president, and secretary
Mar 05, 2024	patel sujal m	bought	19,596	2.6464	7,405	ceo, president, and secretary
Sep 27, 2022	sankar subramanian	bought	10,149	2.0298	5,000	senior vp, product development
Sep 26, 2022	sankar subramanian	bought	20,250	2.025	10,000	senior vp, product development
Sep 23, 2022	weld gwen e	bought	60,765	2.0255	30,000	chief people officer
Sep 16, 2022	sankar subramanian	bought	75,446	2.1556	35,000	senior vp, product development
Sep 15, 2022	sankar subramanian	bought	87,752	2.1938	40,000	senior vp, product development

Which funds bought or sold NAUT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.92	-9,923	14,921	-%
May 16, 2024	COMERICA BANK	unchanged	-	-61.00	3,554	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-41.63	-67,117	90,420	-%
May 15, 2024	Voya Investment Management LLC	reduced	-15.91	-11,094	52,970	-%
May 15, 2024	Royal Bank of Canada	reduced	-93.01	-47,000	3,000	-%
May 15, 2024	SENTINEL TRUST CO LBA	added	3.33	14,000	911,000	0.12%
May 15, 2024	PERCEPTIVE ADVISORS LLC	unchanged	-	-629,710	37,027,000	0.64%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	84.65	27,257	60,673	-%
May 15, 2024	Alyeska Investment Group, L.P.	unchanged	-	-22,051	1,296,590	0.01%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-15.03	-2,261	11,484	-%

Are Funds Buying or Selling NAUT?

Are funds buying NAUT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NAUT

No. of Funds

Unveiling Nautilus Biotechnology, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 17, 2023	perceptive advisors llc	10.1%	12,594,211	SC 13D/A
Mar 01, 2023	nautilus biotechnology, inc.	15.0%	18,947,732	SC 13D/A
Feb 13, 2023	cercano management llc	5.8%	7,172,985	SC 13G
Feb 14, 2022	ra capital management, l.p.	2.0%	2,436,430	SC 13G/A
Feb 10, 2022	vcvc v llc	2.9%	3,586,493	SC 13G

Recent SEC filings of Nautilus Biotechnology, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 30, 2024	10-Q	Quarterly Report
Apr 30, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Mar 11, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 06, 2024	EFFECT	EFFECT
Mar 06, 2024	424B5	Prospectus Filed
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to Nautilus Biotechnology, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Nautilus Biotechnology, Inc. News

Latest updates

Nautilus Biotechnology, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-5.5%	289	306	318	331	346	350	359	372	385	398	385	393	76.00	85.00	151	85.00	19.00
Current Assets	4.7%	185	177	187	167	170	187	261	303	327	349	352	375	69.00	78.00	1.00	-	17.00
Cash Equivalents	32.6%	26.00	19.00	74.00	72.00	89.00	115	190	211	189	186	191	289	52.00	37.00	13.00	33.00	1.00
Net PPE	6.0%	5.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	1.00	-	-	1.00
Liabilities	-2.6%	39.00	40.00	41.00	41.00	42.00	35.00	34.00	34.00	35.00	35.00	8.00	3.00	5.00	6.00	5.00	-	0.00
Current Liabilities	1.0%	9.00	9.00	9.00	8.00	8.00	7.00	6.00	6.00	6.00	6.00	4.00	3.00	5.00	3.00	0.00	0.00	0.00
Shareholder's Equity	-6.0%	249	265	277	290	304	315	325	338	350	364	378	390	5.00	5.00	5.00	0.00	-
Retained Earnings	-9.3%	-221	-202	-185	-169	-153	-138	-125	-111	-96.40	-80.64	-64.00	-49.40	-38.73	-30.32	-0.17	-0.01	-14.71
Additional Paid-In Capital	0.7%	471	468	465	461	458	455	452	449	447	444	442	439	2.00	1.00	5.00	0.00	0.00
Accumulated Depreciation	11.0%	5.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	1.00	1.00	-	-	1.00
Shares Outstanding	0.2%	125	125	125	125	125	125	125	124	124	124	71.00	44.00	-	-	-	-	-
Float	-	-	-	-	219	-	-	-	152	-	-	-	571	-	-	-	168	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-17.0%	-16,266	-13,900	-11,738	-13,549	-12,524	-10,377	-9,565	-13,529	-12,335	-10,519	-14,177	-8,292	-6,253	-4,727	-3,371	-	-2,621	-
Share Based Compensation	1.3%	3,114	3,073	3,106	3,098	2,860	2,833	2,870	2,567	2,110	2,530	2,248	1,820	1,336	250	59.00	41.00	19.00	-
Cashflow From Investing	154.4%	22,353	-41,060	13,075	-2,255	-13,495	-64,055	-11,943	35,076	15,182	6,064	-83,980	-84,566	23,518	28,696	-16,288	-45,573	7,886	-
Cashflow From Financing	-3.2%	245	253	16.00	98.00	1.00	135	86.00	185	156	63.00	11.00	329,442	-2,069	-	28.00	75,861	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NAUT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 12,930	$ 10,877
General and administrative	8,677	7,183
Total operating expenses	21,607	18,060
Other income (expense)
Interest income	2,877	3,098
Other expense	0	(3)
Total other income	2,877	3,095
Net loss	$ (18,730)	$ (14,965)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.15)	$ (0.12)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.15)	$ (0.12)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	125,135,451	124,590,351
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	125,135,451	124,590,351

NAUT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 25,729	$ 19,397
Short-term investments	155,637	154,021
Prepaid expenses and other current assets	3,728	3,419
Total current assets	185,094	176,837
Property and equipment, net	4,525	4,267
Operating lease right-of-use assets	31,559	32,634
Long-term investments	66,292	90,647
Other long-term assets	1,180	1,180
Total assets	288,650	305,565
Current liabilities:
Accounts payable	1,860	1,639
Accrued expenses and other liabilities	3,677	3,945
Current portion of operating lease liabilities	3,675	3,538
Total current liabilities	9,212	9,122
Operating lease liabilities, net of current portion	29,946	31,090
Total liabilities	39,158	40,212
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.0001 par value, 200,000,000 authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value, 1,000,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 125,265,015 and 125,068,601 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	13	13
Additional paid-in capital	471,193	467,834
Accumulated other comprehensive income (loss)	(745)	(255)
Accumulated deficit	(220,969)	(202,239)
Total stockholders’ equity	249,492	265,353
Total liabilities and stockholders' equity	$ 288,650	$ 305,565

About Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was incorporated in 2016 and is headquartered in Seattle, Washington.

CEO	Mr. Sujal M. Patel
WEBSITE	nautilus.bio
INDUSTRY	Biotechnology
EMPLOYEES	153

Nautilus Biotechnology, Inc. Frequently Asked Questions

What is the ticker symbol for Nautilus Biotechnology, Inc.? What does NAUT stand for in stocks?

NAUT is the stock ticker symbol of Nautilus Biotechnology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nautilus Biotechnology, Inc. (NAUT)?

As of Fri May 17 2024, market cap of Nautilus Biotechnology, Inc. is 372.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NAUT stock?

You can check NAUT's fair value in chart for subscribers.

What is the fair value of NAUT stock?

You can check NAUT's fair value in chart for subscribers. The fair value of Nautilus Biotechnology, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nautilus Biotechnology, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NAUT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nautilus Biotechnology, Inc. a good stock to buy?

The fair value guage provides a quick view whether NAUT is over valued or under valued. Whether Nautilus Biotechnology, Inc. is cheap or expensive depends on the assumptions which impact Nautilus Biotechnology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NAUT.